Index

abacavir (ABC), 67
ABC-lamivudine (3TC), 68
acetaminophen, 216
achlorhydria, 65, 191–2
actonel, 131
age
age-dependent bone loss, 40
fracture risk assessment, 49
alcoholism, 18
alendronate, 22–3, 24, 25, 83
clinical trial data
registration studies, 128–30
concomitant anabolic and anti-resorptive therapy, 168
followed by denosumab, 202
safety considerations
gastrointestinal, 137
other concerns, 137
anabolic treatment of osteoporosis, 158
anti-resorptive after anabolic therapy, 206–7
anti-resorptive before anabolic therapy, 203–5
parathyroid hormone (PTH), 158–61
anastrozole, 94
androgen deprivation therapy (ADT), 16, 20, 21
antidepressants, 94–5
anti-epileptic drugs (AEDs), 95–6
anti-resorptive therapy, 166–9, 202
after anabolic therapy, 206–7
before anabolic therapy, 203–5
anti-sclerostin therapy, 220–23
anti-tissue transglutaminase antibodies, 69
aromatase inhibitors (AIs), 93–4
atorvastatin, 216
balicatib, 216–17
bariatric surgery, 66
basic multicellular units (BMUs), 32
bone remodeling compartment (BRC), 35–7
bazedoxifene, 114
belief in medication, 242–5
bisclutamide, 18
bisphosphonates, 24, 25, 71–2, 123–4, 138
benefits and risks, 131–3
possible benefits, 138
clinical trial data
bridging studies, 130–31
registration studies, 128–30
concomitant anabolic and anti-resorptive therapy, 169
drug holidays, 133–5
monitoring, 233–4
followed by strontium ranelate, 202–3
glucocorticoid-induced osteoporosis (GIO)
intravenous, 84
oral, 83
new forms, 212–13
pharmacology, 125–8
safety considerations
gastrointestinal, 137
other concerns, 137–8
renal, 135–6
bone diseases, 62
bone formation agents, 84–5
bone fractures
epidemiology, 7–9
etiology, 1–2
geographical influences, 9–10
secular trends, 10–11
bone geometry
fracture risk assessment, 48
bone histomorphometry, 69–70
bone mineral density (BMD), 1
early life development, 5–6
effect of estrogen therapy on bone, 110–11
epigenetics, 5–6
fracture epidemiology, 7–9
fracture risk, 47–8
femoral neck, 51
gene-environment interactions, 5–6
genetics
estrogen pathway, 4
heritability estimates, 2
RANKL-RANK-OPG pathway, 5, 24, 33, 38, 144–5
studies, 2–4
Wnt-β-catenin signaling pathway, 4–5
men, 19–21
monitoring therapy, 228–31
testing technologies, 229
T-scores, 46

Index

bone morphogenic factors (BMPs), 33, 39
bone remodeling mechanisms, 31, 42–3
osteoporosis
age-dependent bone loss, 40
changes during menopause, 40
defective osteoblast function, 41–2
increased bone resorption, 41
secondary, 42
remodeling compartment (BRC), 35–40
remodeling cycle, 31–3
coupling between resorption and formation, 35
osteoblast differentiation, 33–4
osteocyte differentiation, 33
Wnts and osteoblast differential, 34
bone specific alkaline phosphatase (BSAP), 231
bone turnover
fracture risk assessment, 49
markers (BTMs), 231–3
broadband ultrasound attenuation (BUA), 230
calcineurin inhibitors, 96–7
calcitonin, 83
new forms, 212
calcium, 71, 192–6
fracture prevention, 188–90
homeostasis regulation, 183–5
prevention and treatment of deficiency, 191–2
candidate gene association studies (CGAS), 3–4
cathepsin K (CatK) inhibitors, 215, 220
clinical trials, 215–19
preclinical studies, 215–16
role in bone metabolism, 214–15
celiac disease
pathophysiology, 65
childhood environmental influences, 6–7
cholecalciferol (vitamin D3), 180
sources, 181
chronic kidney disease (CKD), 69
clinician’s approach to patients, 247–9, 263, 272
diagnosis, 263–6
interaction with patient, 266–8
osteoporosis in men, 271–2
secondary osteoporosis, 271
treating patients, 268–71
treatment and evidence, 266
cognitive impairment, 241
collagen, abnormal formation, 3
colony stimulating factor (CSF), 39
combination therapy for osteoporosis, 201, 207
anabolic and anti-resorptive therapy
anti-resorptive after anabolic, 206–7
anti-resorptive before anabolic, 203–5
sequential treatment
alendronate and denosumab, 202
bisphosphonates and strontium ranelate, 202–3
collaboration with fracture prevention
medication, 239, 254–5
adherence improving interventions, 250–4
studies, 251–3
barriers to utilization
costs, 246
regimen complexity, 247
social support, 247
consequences of noncompliance, 241–2
epidemiology of nonadherence, 240–41
etiology of nonadherence, 242–5
medication use self-efficacy, 247
perceived benefits from taking medication, 245–6
concerns or mistrust, 246
perceived susceptibility, 246
physician-patient relationship, 247–9
conjugated equine estrogens (CEEs), 108, 112
C-telopeptides (CTX), 49, 215, 231
Cushing’s syndrome, 69
cyclophosphamide, 18
cyclosporine, 96–7
denosumab, 24, 25, 73, 144
administration, 155–6
clinical pharmacology, 144–5
efficacy studies, 146–7
drug-drug interactions, 155
following alendronate, 202
newer indications, 153
phase II trials, 148–50
phase III trials, 150
safety considerations, 153–5
substudies, 150–52
dentin matrix protein 1 (DMP1), 33
deoxyxypyrindinone (DPD), 231
depot medroxyprogesterone acetate (DMPA), 97–8
diabetes mellitus, type 1 (T1DM), 62
pathophysiology, 64–5
diabetes mellitus, type 2 (T2DM), 62
Dickkopf protein 1 (Dkk1), 34
disability adjusted life years (DALYs), 2
DNA methylation, 6
dual energy X-ray absorptiometry (DXA), 19–20, 22, 228, 229
fracture risk assessment, 53
emerging therapies, 211, 223
new forms of current agents
bisphosphonates, 212–13
calcitonin, 212
estrogen agonists/antagonists (EAAs), 211–12
parathyroid hormone, 213
new treatment strategies, 213–14
anti-sclerostin therapy, 220–23
cathepsin K (CatK) inhibitors, 214–20
endothelin, 34
diabetes mellitus, type 1 (T1DM), 64–5
growth hormone deficiency, 65
hypercalciuria, idiopathic, 64
hyperthyroidism
pathophysiology, 62–3
hypogonadism, male, 64
management, 70
pregnancy-associated osteoporosis, 64
endothelin, 34
environmental influences
childhood, 6–7
gene-environment interactions, 5–6
epigenticity of postmenopausal osteoporosis, 5–6
ergocalciferol (vitamin D$_2$), 180
sources, 181
estimated glomerular filtration rate (eGFR), 135–6
estradiol, 112
in men, 19
transdermal patches, 115
estrogen, 108
agonists/antagonists (EAAs), 211–12
benefits and risks of therapy, 117
effect of estrogen therapy on bone, 110
BMD changes, 110–11
fractures, 111–12
lower dose estrogen therapy, 114
pathway to osteoporosis, 4, 109
Extended Health Belief Model, 244–5
fall prevention, 191
farnesyl pyrophosphate synthetase (FFPS), 125, 127
femoral neck BMD, 51
fibroblast growth factor (FGF), 33, 39
fibromyalgia, 188
fluoxetine, 95
fosamax, 131
fracture prevention, 188–90
fracture risk assessment, 46, 55–6
age, 49
bone geometry, 48
bone mineral density (BMD), 47–8
bone turnover, 49
FRAX$^\text{R}$ tool, 49–50
calculation without BMD, 53–4
dichotomised response, 50–51
femoral neck BMD, 51
further development, 54
management decisions, 50
patient follow up, 50
risk factors not included, 51–3
Garvan Fracture Risk Calculator (FRC), 54
other factors, 49
fractures, 1
effect of estrogen therapy on bone, 111–12
epidemiology, 7–9
etiology, 1–2
geographical influences, 9–10
secular trends, 10–11
FRAX$^\text{R}$ tool, 1, 20–21, 49–50, 80
calculation without BMD, 53–4
dichotomised response, 50–51
femoral neck BMD, 51
further development, 54
management decisions, 50
patient follow up, 50
risk factors not included, 51–3
freedom trial substudies, 150–52
Garvan Fracture Risk Calculator (FRC), 54
gastrointestinal diseases
celiac disease, 65
gastrectomy, 66
inflammatory bowel disease, 65–6
management, 70–71
proton pump inhibitor therapy, chronic, 66
Gauker disease (GD), 68
genetic factors for osteoporosis (GEPOS), 4
genetic markers of osteoporosis (GENOMOS), 4
epidemiology, 79–80
FRAX$^\text{R}$ tool, 80
management guidelines, 85–6
algorithm, 88
American College of Rheumatology (ACR), 85–6, 87
IOF, 86–90
National Osteoporosis Foundation (NOF), 85
parathyroid hormone (PTH) therapy, 165
pathophysiology, 81–2
treatment, 82–3
bisphosphonates, intravenous, 84
bisphosphonates, oral, 83
bone formation agents, 84–5
other agents, 83
workup, 80
glucocorticoids, 16, 18, 20
glyburide, 101
glycogen synthase kinase 3 (GSK3), 34
gonadotropin releasing hormone (GnRH) agonists, 98–9
goserelin, 99
Graves’ disease, 65
growth hormone deficiency
pathophysiology, 65
Health Belief Model, 244–5
hematological diseases
mononclonal gammopathy of undetermined significance (MGUS), 66–7
myeloma bone disease, 66–7
highly active retroviral therapy (HAART), 67–8
hip axis length (HAL), 48
HIV disease, 67–8
hormone replacement therapy (HRT), 41
hormone therapy (HT) for osteoporosis, 108, 117–18
benefits and risks of estrogen therapy, 117
effect of estrogen therapy on bone, 110
BMD changes, 110–11
fractures, 111–12
mechanism of action, 109–10
specific compounds, 112–14
administration route, 115–16
Index

hormone therapy (HT) for osteoporosis (Continued)
cessation of therapy, 116–17
duration of therapy, 116
lower dose estrogen therapy, 114
human growth hormone (hGH), 6, 65
human parathyroid hormone, recombinant (rhPTH), 84
25-hydroxyvitamin D [25(OH)D], 184, 185–7
hypercalcemia, idiopathic
pathophysiology, 64
hyperparathyroidism, 18, 41, 42
hyperparathyroidism, primary (PHPT)
pathophysiology, 63–4, 158–61
hypothyroidism, 18, 22
pathophysiology, 62–3
hypogonadism, 17, 18
hypogonadism, male
pathophysiology, 64
ibandronate, 24
clinical trial data
registration studies, 128–30
safety considerations
gastrointestinal, 137
other concerns, 137
ibuprofen, 216
IGF-binding proteins (IGFBPs), 65
iliac crest bone biopsy, 69–70
immunological diseases
Gaucher disease (GD), 68
highly active retroviral therapy (HAART), 67–8
HIV disease, 67–8
inflammatory bowel disease
pathophysiology, 65–6
insulin-like growth factor I (IGF-I), 16, 33, 39, 65
interleukins (IL), 39
Kallman’s syndrome, 18
ketocazole, 18
Klinefelter’s syndrome, 18
lamotrigine, 96
lasofoxifene, 114
least significant change (LSC), 228–9
leuprolide, 19, 99
malabsorption, 18
mascocytosis, systemic, 67
medroxyprogesterone acetate, depot (DMPA), 97–8
medroxyprogesterone acetate (MPA), 108
melanin, 180–82
men, osteoporosis in, 15
classification, 16–17
clinician’s approach to patients, 271–2
diagnosis and evaluation, 19–22
epidemiology, 15–16
management, 72–3
pathophysiology, 17–19
teriparatide, 164–5
treatment, 22–6
metformin, 101
monitoring therapy, 227–8, 235
adherence and safety, 233
bisphosphonate drug holiday, 233–4
bone density testing, 228–31
bone turnover markers (BTMs), 231–3
suboptimal responder evaluation, 234
monoclonal gammopathy of undetermined significance (MGUS), 66–7
mortality in men following hip fracture, 16, 26
mutations
DNA methylation, 6
single gene, 3
myeloma bone disease, 66–7
national osteoporosis foundation (NOF), 50
new treatment strategies, 213–14
anti-sclerostin therapy, 220–23
cathepsin K (CatK) inhibitors, 214–20
nilutamide, 18
nitric oxide (NO), 39
nonadherence
barriers to utilization
costs, 246
regimen complexity, 247
social support, 247
epidemiology, 240–41
etiology, 242–5
primary, 239
secondary, 239
noncompliance, 239
consequences, 241–2
nonpersistence, 239
consequences, 241–2
N-telepeptides (NTX), 49, 215, 231
obesity and vitamin D deficiency, 182
odanacatib, 216, 218–19
omeprazole, 66, 99–100
orchiis, 18
ostenteclin, 34
osteoblasts
defective function in osteoporosis, 41–2
differentiation, 33–4
Wnt-β-catenin signaling pathway, 34
osteocalcin (OC), 33, 34, 231
osteocyte differentiation, 33
osteogenesis imperfecta, 3
osteomalacia, 188
osteonecrosis of the jaw (ONJ), 132
osteopenia, 50
osteopontin, 34
osteoporosis
definition, 1
etiology of fractures, 1–2
genetics, 1
postmenopausal, see postmenopausal osteoporosis
pregnancy-associated, 64
secondary, 62, 73–4, 93, 102–3
antidepressants, 94–5
anti-epileptic drugs (AEDs), 95–6
aromatase inhibitors (AIs), 93–4
bariatric surgery, 66
calcineurin inhibitors, 96–7
causes, common, 63
causes, less-common, 63
clinician’s approach to patients, 271
depot medroxyprogesterone acetate (DMPA), 97–8
diagnosis, 68–70
endocrine diseases, 62–5
gastrointestinal diseases, 65–6
gonadotropin releasing hormone (GnRH) agonists, 98–9
hematological and immunological diseases, 66–8
management, 70–73
parathyroid hormone (PTH) therapy, 165
proton pump inhibitors (PPIs), 99–101
thiazolidinediones (TZDs), 101–2
osteoporosis-pseudoglioma syndrome, 3, 4
osteoprotegerin (OPG), 5, 145
parathyroid hormone (PTH), 39, 158, 173
as an anabolic agent, 158–61
consequences of discontinuing therapy, 169–72
future directions, 172–3
indications, 165–6
monitoring therapy, 166
new forms, 213
postmenopausal osteoporosis monotherapy, 162–4
PTH (1-84), 164
safety considerations, 172
secondary osteoporosis, 165
sequential and combination therapy
concomitant anabolic and anti-resorptive therapy, 168–9
previous use of anti-resorptive drugs, 166–8
teriparatide in men with osteoporosis, 164–5
patients’ concerns about medications, 243, 245, 246
percent days covered (PDC), 240
peripheral DXA (pDXA), 228, 229
peripheral QCT (pQCT), 228, 229
peroxisome proliferator-activated receptor gamma (PPARγ), 102
 persistence with fracture prevention medication, 239, 240, 254–5
adherence improving interventions, 250–54
 barriers to utilization
costs, 246
 regimen complexity, 247
 social support, 247
 consequences of nonpersistence, 241–2
epidemiology of nonadherence, 240–41
 etiology of nonadherence, 242–5
 medication use self-efficacy, 247
 perceived benefits from taking medication, 245–6
 concerns or mistrust, 246
 perceived susceptibility, 246
 physician-patient relationship, 247–9
phenothiazines, 18
phenytoin, 96
phosphorus
homeostasis regulation, 183–5
physician-patient relationship, 247–9, 272
diagnosis, 263–6
interaction with patient, 266–8
osteoporosis in men, 271–2
secondary osteoporosis, 271
treating patients, 268–71
treatment and evidence, 266
pioglitazone, 101–2
platelet-derived growth factors (PDGF), 39
postmenopausal osteoporosis, 1–2, 11
bone remodeling changes, 40
childhood environmental influences, 6–7
everal life development, 5–6
epigenetics, 5–6
fracture epidemiology, 7–9
gene-environment interactions, 5–6
 genetics, 1
 estrogen pathway, 4
 heritability estimates, 2
 RANKL-RANK-OPG pathway, 5, 24
 Wnt-β-catenin signaling pathway, 4–5
 geography, 9–10
 parathyroid hormone (PTH) monotherapy, 165
 PTH (1-84), 164
 secular trends, 10–11
 prednisone, 16, 18
 fracture risk assessment, 51
 pregnancy-associated osteoporosis
 pathophysiology, 64
 pro-collagen type 1 N-propeptide (PINP), 231
 progestin, 108, 112
Prolia® administration, 155–6
drug-drug interactions, 155
 newer indications, 153
 safety considerations, 153–5
 prostate cancer, 20
 proton pump inhibitors (PPIs), 99–101
 chronic use pathophysiology, 66
 quantitative computed tomography (QCT)
 110, 228, 229
 quantitative ultrasound (QUS) 228, 229
 raloxifene, 83, 112–14
 randomized controlled trials (RCTs), 227
 RANKL-RANK-OPG pathway to osteoporosis, 5, 24, 33, 38, 144–5
 relacatib, 216
 risedronate, 23, 24, 25, 83
 clinical trial data
 registration studies, 128–30
 safety considerations
 gastrointestinal, 137
other concerns, 137
romosozumab, 221
rosiglitazone, 101–2
runx-related transcription factor 2 (Runx2), 33
sclerostosis, 34
sclerostin, 33, 34
anti-sclerostin therapy, 220–23
secondary osteoporosis, 73–4, 93, 102–3
antidepressants, 94–5
anti-epileptic drugs (AEDs), 95–6
aromatase inhibitors (AIs), 93–4
bariatric surgery, 66
calcineurin inhibitors, 96–7
clinician’s approach to patients, 271
depot medroxyprogesterone acetate (DMPA), 97–8
diagnosis, 68–70
diabetes mellitus, type 1 (T1DM), 64–5
growth hormone deficiency, 65
hypercalcemia, idiopathic, 64
hypoparathyroidism, male, 64
pregnancy-associated osteoporosis, 64
gastrointestinal diseases
celiac disease, 65
gastrectomy, 66
inflammatory bowel disease, 65–6
proton pump inhibitor therapy, chronic, 66
gonadotropin releasing hormone (GnRH) agonists, 98–9
hyperparathyroidism, primary (PHPT) pathophysiology, 63–4
hypothyroidism
pathophysiology, 62–3
management, 70
bisphosphonates, 71–2
calcium, 71
endocrine diseases, 70
gastrointestinal diseases, 70–71
vitamin D, 71
parathyroid hormone (PTH) therapy, 165
proton pump inhibitors (PPIs), 99–101
thiazolidinediones (TZDs), 101–2
secular trends, 10–11
selective estrogen receptor modulators (SERMs), 109, 112–14, 211–12
selective serotonin reuptake inhibitors (SSRIs), 94–5
self-efficacy, 247
single nucleotide polymorphisms (SNPs), 3
estrogen pathway to osteoporosis, 4
RANKL-RANK-OPG pathway to osteoporosis, 5
skeletal related events, 132
speed of sound (SOS) measurement, 230
spironolactone, 18
strontium ranelate, 202–3
sun protection factor (SPF), 182
tacrolimus, 96–7
tamoxifen, 94
tDF-emtricitabine, 67–8
telopeptides, 49
tenovolin (TDF), 67
teriparatide, 24–5, 72, 158
indications, 165–6
men with osteoporosis, 164–5
sequential and combination therapy
concomitant anabolic and anti-resorptive therapy, 168–9
previous use of anti-resorptive drugs, 166–8
testosterone replacement therapy, 19
thiazolidinediones (TZDs), 101–2
thyrotoxicidones, 42
tibolone, 112
transdermal HRT administration, 115
transforming growth factor (TGF), 39
management, 70
bisphosphonates, 71–2
calcium, 71
endocrine diseases, 70–71
vitamin D, 71
parathyroid hormone (PTH) therapy, 165
proton pump inhibitors (PPIs), 99–101
thiazolidinediones (TZDs), 101–2
sex trends, 10–11
selective estrogen receptor modulators (SERMs), 109, 112–14, 211–12
selective serotonin reuptake inhibitors (SSRIs), 94–5
self-efficacy, 247
single nucleotide polymorphisms (SNPs), 3
estrogen pathway to osteoporosis, 4
RANKL-RANK-OPG pathway to osteoporosis, 5
skeletal related events, 132
speed of sound (SOS) measurement, 230
spironolactone, 18
strontium ranelate, 202–3
sun protection factor (SPF), 182
tacrolimus, 96–7
tamoxifen, 94
tDF-emtricitabine, 67–8
telopeptides, 49
tenovolin (TDF), 67
teriparatide, 24–5, 72, 158
indications, 165–6
men with osteoporosis, 164–5
sequential and combination therapy
concomitant anabolic and anti-resorptive therapy, 168–9
previous use of anti-resorptive drugs, 166–8